Ibogaine for Health & Longevity

Evidence Review created on 08/04/2026 using AI4L / Opus 5

Also known as: Iboga, Tabernanthe iboga, Ibogaine Hydrochloride, Ibogaine HCl, Endabuse

Motivation

Ibogaine is a psychoactive compound from the root bark of a Central African shrub (Tabernanthe iboga), used for centuries in Gabonese ceremonial traditions and, since the 1960s, taken by people trying to interrupt drug dependence. What draws attention beyond dependence is the claim attached to it: that a single session can produce lasting changes in mood, motivation, and mental clarity, apparently by prompting the brain to rebuild connections rather than by acting day after day the way a conventional medication does.

Interest has widened well past dependence. Military veterans have travelled to clinics abroad seeking relief from the lasting effects of head injury and combat stress, a state legislature has committed public money to formal trials, and biotechnology companies are designing related molecules. At the same time, ibogaine carries a documented risk of dangerous heart-rhythm disturbances, and deaths have occurred.

This review examines what the evidence shows about ibogaine for people focused on long-term health and function: how it is thought to work, what benefits have been measured and how firmly, what harms have been recorded, how it is used in practice, and where the evidence remains thin.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Ibogaine

A dense reference entry covering the alkaloid’s chemistry, receptor pharmacology, metabolism to noribogaine, the documented cardiac toxicity, the ethnobotanical and underground treatment history, and the current legal patchwork. Its value here is breadth and the country-by-country regulatory detail, which is otherwise scattered across many sources.

Examine

No Examine article exists for ibogaine. Examine.com covers dietary supplements and nutrition compounds; it does not cover prescription medications or scheduled controlled substances, and ibogaine is a Schedule I controlled substance in the United States (the most restrictive category, reserved for compounds held to have no accepted medical use) rather than a dietary supplement.

ConsumerLab

No ConsumerLab article or product review exists for ibogaine. ConsumerLab tests and reviews commercially sold dietary supplements; it does not cover prescription medications or controlled substances, and ibogaine is not legally sold as a supplement in the United States.

Systematic Reviews

The papers below are the systematic reviews (structured searches of all available studies on a question) and meta-analyses (statistical pooling of results across studies) that define what is currently known about ibogaine’s efficacy and safety.

A systematic literature review of clinical trials and therapeutic applications of ibogaine - Köck et al., 2022

The most comprehensive synthesis of human data, covering 24 studies and 705 treated individuals, including three controlled trials among them two randomized double-blind studies (a randomized controlled trial, or RCT, assigns participants to treatment or comparison by chance to reduce bias). It concludes that ibogaine reduces withdrawal symptoms and craving and may improve depressive and trauma-related symptoms, while documenting severe medical complications and two deaths within the included studies.
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature - Mosca et al., 2023

A systematic review with a pooled analysis of side effects across the eligible studies, finding a significant excess of headache after ibogaine or noribogaine. Its conclusion is deliberately two-sided: efficacy signals in substance use disorders are real but the cardiotoxicity and mortality record is described by the authors as worrying.
The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020) - Ona et al., 2022

The dedicated safety synthesis, classifying adverse events into acute effects within 24 hours — dominated by prolongation of the QT interval (the portion of the heart’s electrical cycle covering ventricular contraction and recovery) — and effects persisting beyond 24 hours, including persistent cardiac, psychiatric and neurological findings. It is the single best source for understanding what actually goes wrong and when.
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies - Rocha et al., 2023

Rather than asking whether ibogaine works, this review asks which administration conditions reduce harm, synthesising 12 clinical studies to conclude that trained staff, formal screening, and continuous medical, psychiatric and cardiac monitoring are the determining safety variables. For anyone evaluating a specific provider, this is the most directly usable paper in the literature.
Ibogaine and addiction in the animal model, a systematic review and meta-analysis - Belgers et al., 2016

A meta-analysis of 27 animal studies showing that ibogaine reduces drug self-administration — most strongly in the first 24 hours — while producing no change in conditioned place preference (a standard animal measure of how strongly a drug’s associated surroundings become rewarding), alongside motor impairment within the first day and cerebellar cell loss detectable weeks later. It is the strongest quantitative evidence base ibogaine has, and it is preclinical, which is itself the central limitation of the field.

Mechanism of Action

Ibogaine is unusual among psychoactive compounds in that it has no single primary target. It binds many receptors and transporters with low (micromolar) affinity rather than one with high affinity, a profile sometimes described as matrix or polypharmacology, and its therapeutic effects are generally attributed to the combination rather than to any one interaction.

Nicotinic receptor blockade: Ibogaine antagonises the α3β4 subtype of the nicotinic acetylcholine receptor (a receptor for acetylcholine, the signalling chemical used by nerves to activate muscles and to modulate reward circuitry), which is concentrated in the habenula and interpeduncular nucleus — a pathway that brakes reward signalling. This is the most frequently proposed explanation for the reduction in craving across several drug classes rather than one.
Glutamate and opioid receptor effects: Ibogaine is a weak non-competitive antagonist at the NMDA (N-methyl-D-aspartate) receptor, a glutamate receptor central to learning and memory, an action shared with ketamine and linked to rapid antidepressant effects. Both ibogaine and its metabolite act at κ-opioid (kappa) receptors, which mediate dysphoria and dissociation, and noribogaine behaves as a weak μ-opioid (mu) receptor agonist, which plausibly contributes to the immediate relief of opioid withdrawal.
Serotonin transporter modulation: Ibogaine and noribogaine bind the serotonin transporter (SERT, the protein that pulls serotonin back into nerve cells after release), but recent structural work shows they occupy an inward-facing conformation distinct from that used by conventional antidepressants, producing a different functional consequence than simple reuptake blockade.
Sigma and dopamine effects: Ibogaine has appreciable affinity for the sigma-2 receptor (a protein involved in cell stress responses, implicated in some of the compound’s neurotoxic potential at high doses), and it indirectly modulates dopamine release in the ventral tegmental area (VTA, the midbrain source of the brain’s reward-signalling dopamine neurons).
Growth-factor induction: In rodents, ibogaine and noribogaine raise expression of GDNF (glial cell line-derived neurotrophic factor, a protein that supports the survival and repair of dopamine neurons) in the VTA, and ibogaine alters expression of BDNF (brain-derived neurotrophic factor, the equivalent growth factor for broader neural repair and connection-building). This is the mechanism most often invoked to explain why a single dose could produce effects lasting weeks — the drug is gone, but the structural change it triggered is not.

Where the mechanistic accounts genuinely compete is on whether the subjective experience matters. One position holds that the anti-craving effect is purely pharmacological: it appears in rodents that cannot have a psychological insight, and non-hallucinogenic analogues such as 18-MC (18-methoxycoronaridine, a synthetic iboga-type molecule engineered to drop the visionary effect) and tabernanthalog reduce drug self-administration in animals without producing an altered state. The opposing position holds that in humans the prolonged oneiric state (a dream-like waking experience, ibogaine’s signature effect) does the therapeutic work, and points to human data in which the intensity of that experience predicts the size of the symptom improvement. The two accounts are not mutually exclusive and both remain live; the analogue programmes now in development are, in effect, an experiment to settle the question.

Key pharmacological properties:

Metabolism and enzymes: Ibogaine undergoes rapid first-pass O-demethylation, primarily by CYP2D6 (a liver enzyme that breaks down a large share of psychiatric and cardiac medications and whose activity varies widely between individuals), to the active metabolite noribogaine (12-hydroxyibogamine). CYP2C9 and CYP3A4 (two further liver drug-metabolising enzymes) contribute minor pathways. Clearance is strongly tied to CYP2D6 genotype: clearance rises by roughly 31 litres per hour for each point of CYP2D6 activity score, so the same milligram-per-kilogram dose can produce several-fold different blood levels between individuals.
Half-life: Ibogaine’s own plasma half-life is short and highly variable, commonly in the range of four to eight hours in normal metabolisers. Noribogaine is eliminated far more slowly, with a mean half-life of 28–49 hours measured across dose groups in a healthy-volunteer study, meaning meaningful exposure persists for several days after a single administration.
Selectivity and distribution: Selectivity is low by design of nature rather than intent — affinities cluster in the low-micromolar range across at least six target families. Both compounds dissolve far more readily in fat than in water, giving a very large apparent volume of distribution (mean 1,417–3,086 litres for noribogaine) and concentrating them in fat tissue and brain, where levels substantially exceed plasma levels and from which the compound redistributes slowly.
Cardiac target: Both ibogaine and noribogaine block the hERG potassium channel (the human ether-à-go-go-related gene channel, which carries the current that resets heart muscle cells electrically after each beat), with half-maximal inhibitory concentrations of approximately 3.5 and 2.9 micromolar respectively. This is not a side pathway; it is the direct explanation for the compound’s principal danger.

Historical Context & Evolution

Original use: Ibogaine’s original context is ethnobotanical, not medical. Root bark of Tabernanthe iboga has been used for centuries in Gabon and neighbouring countries — at low doses as a stimulant to suppress fatigue, hunger and thirst during hunting, and at high doses as the central sacrament of the Bwiti initiatory tradition, where the multi-day visionary state is understood as contact with ancestors. Isolated in 1901, ibogaine entered European pharmacology as a stimulant tonic: in France, tablets containing 8 mg of ibogaine were sold under the name Lambarène from the late 1930s until the compound was withdrawn from the market around 1970.
How it came to health optimization: The pivot came from a lay observation, not a laboratory. In 1962 a 19-year-old heroin-dependent New Yorker, Howard Lotsof, took ibogaine recreationally and reported that his withdrawal symptoms and craving had vanished without the expected withdrawal syndrome. He spent decades documenting similar reports and obtained United States patents in the 1980s for ibogaine as an addiction interrupter under the name Endabuse. That single anecdotal chain — not a hypothesis-driven programme — is why ibogaine is studied at all today, and it is also why the field carries an unusually heavy legacy of advocacy alongside its data.
What the historical research actually found: The 1990s brought the first serious preclinical and clinical work. Animal studies at Albany Medical College showed dose-dependent reductions in morphine and cocaine self-administration persisting well beyond the drug’s presence in the body. Concurrently, O’Hearn and Molliver reported that 100 mg/kg of ibogaine injected into the abdominal cavity of rats produced degeneration of Purkinje cells (the large output neurons of the cerebellum, the brain region coordinating balance and fine movement), apparently through overstimulation of the inferior olive rather than direct toxicity. The critical detail, often omitted when this work is summarised, is the dose dependence: no comparable neurodegeneration was found at doses at or below 25 mg/kg, and the finding has not been reproduced in primates at doses in the human therapeutic range.
The funding reversal and what changed: The United States National Institute on Drug Abuse, which had supported ibogaine work, discontinued its development programme in the mid-1990s. The reasons were mixed — the cerebellar findings, the cardiac signal, and commercial and patent disputes with the compound’s advocates all contributed. A parallel programme run by Deborah Mash treated several hundred patients on St. Kitts under an approved protocol and reported withdrawal resolution and craving reduction, but did not convert into a registered pivotal trial. Formal development stalled; informal use did not, and a documented medical subculture of clinics grew across Mexico, Central America, the Caribbean and Europe.
Where the position stands now, and why it moved: The current re-engagement of academic medicine with ibogaine was driven by new evidence on both sides rather than a change of opinion. On one side: a prospective study in veterans published in a mainstream medical journal, pharmacokinetic work identifying CYP2D6 genotype as the main driver of variable exposure, and the demonstration that magnesium co-administration may blunt the cardiac signal. On the other: an updated adverse-event synthesis confirming persistent cardiac abnormalities beyond 24 hours, and continued case reports of arrhythmia at therapeutic doses in people with no prior cardiac history. Neither the earlier reluctance nor the current optimism is the final word; what has changed is that the specific mechanism of the harm is now understood well enough to be screened for and possibly engineered out.

Expected Benefits

High 🟩 🟩 🟩

No benefit of ibogaine currently reaches this evidence threshold. No adequately powered, blinded, placebo-controlled trial has been completed for any indication, so no effect has been established at the level of replicated high-quality trial evidence.

Medium 🟩 🟩

Rapid Suppression of Opioid Withdrawal

A single dose typically ends the physical withdrawal syndrome within hours rather than the usual four to ten days, and does so without substituting another opioid. The proposed mechanism is combined: weak μ-opioid agonism by noribogaine covers the acute gap, while nicotinic and NMDA receptor effects appear to interrupt the withdrawal cascade itself. The evidence base is the 24 studies and 705 individuals covered by the 2022 systematic review, which included two randomized double-blind trials, plus consistent observational cohorts; the main limitations are very small sample sizes, mostly open-label designs, and self-selected populations. It is the most reproducible effect ibogaine has, but the trials establishing it are far smaller than would normally support a confident grade.

Magnitude: Withdrawal scores on the Subjective Opioid Withdrawal Scale (a self-rated 16-item symptom checklist) fell significantly within hours of a single dose in a 14-participant New Zealand cohort (p = 0.015, meaning a result this large would occur by chance about 1.5 times in 100), and relief sufficient to avoid further detoxification medication within 24–48 hours was the typical reported outcome across the pooled clinical literature.

Reduced Craving and Sustained Reduction in Opioid Use

Beyond acute withdrawal, the more consequential claim is that craving stays suppressed for weeks to months after the compound has cleared, giving a window in which behavioural change is possible. The mechanism most often proposed is growth-factor induction in reward circuitry producing durable structural change rather than ongoing receptor occupancy. Evidence comes from observational cohorts with follow-up out to 12 months in New Zealand and to 12 months in a Mexican clinic series, both showing sustained reductions in addiction-severity scores. No cohort had a control group, and attrition was substantial — in the New Zealand study only 8 of 14 participants completed all interviews.

Magnitude: The drug-use composite of the Addiction Severity Index-Lite (a standardised interview scoring the severity of substance-related problems) fell significantly from baseline to 12 months among completers in the New Zealand cohort (p = 0.002), and in a 30-participant Mexican clinic series roughly half of participants reported no opioid use in the 30 days after treatment.

This is the benefit that moved ibogaine from addiction medicine into general interest, and the one most relevant to a health-optimising audience with a history of concussion or blast exposure. The proposed mechanism is the same growth-factor and neuroplasticity account, with the prolonged visionary state possibly contributing an additional psychological effect. The evidence is a prospective open-label study of 30 male special-operations veterans and an independent retrospective survey of 86 veterans, both reporting very large improvements sustained to one and six months respectively; neither had a control group, both drew on people who had already chosen and paid for treatment, and the retrospective survey confounded ibogaine with a second psychedelic given on a separate occasion.

Magnitude: One month after a single magnesium-ibogaine session, within-group effect sizes were Cohen’s d = 2.54 for trauma-related symptoms, 2.80 for depression and 2.13 for anxiety, with disability scores improving at d = 2.20 (Cohen’s d expresses change in standard deviations; values above 0.8 are conventionally large, so these are exceptionally large and would be expected to shrink in a controlled trial).

Low 🟩

Improvement in Cognitive Performance After Repeated Head Trauma

Separate from mood, participants in the veteran studies showed measurable gains in processing speed, executive function and self-reported concentration. The proposed mechanism is repair of white-matter and network-level disruption from repeated blast exposure, supported by follow-on electroencephalography work showing persistent changes in cortical rhythm after treatment. The evidence base is two uncontrolled cohorts in a single, highly specific population; practice effects on repeated cognitive testing are an unaddressed confound.

Magnitude: Processing-speed and executive-function test scores improved from baseline to one month in the 30-participant Stanford cohort, and self-reported memory and concentration problems decreased in the 86-veteran survey and remained improved at six months.

Measurable Structural Brain Change After Repeated Head Trauma

The one benefit supported by an objective, operator-independent measure rather than a questionnaire is a change in brain structure itself, seen on magnetic resonance imaging after a single magnesium-ibogaine session. The proposed mechanism is the growth-factor and structural-plasticity account, with cortical and subcortical tissue changes as its anatomical expression. The evidence is a single uncontrolled imaging cohort — the same 30 special-operations veterans as the parent study — with scans at baseline, immediately after treatment and one month later; short-interval structural imaging is also sensitive to hydration, inflammation and other non-structural influences, which the authors state explicitly. The finding is the most directly longevity-relevant result ibogaine has produced, and it is also the one most in need of a controlled replication.

Magnitude: Predicted brain age fell by 1.3 years at one month relative to baseline, with increased cortical thickness in 11 regions and volumetric expansion in 8 subcortical regions.

Reduced Alcohol and Stimulant Use ⚠️ Conflicted

Ibogaine’s anti-craving effect is claimed to generalise across substance classes, including alcohol, cocaine and methamphetamine, on the basis of its nicotinic and dopaminergic actions rather than any opioid effect. The evidence is genuinely conflicted: pooled animal data show a clear reduction in self-administration but no effect at all on conditioned place preference, an established measure of drug-associated reward learning, a divergence that is difficult to reconcile if the compound truly resets reward valuation. Human data outside opioids are close to absent — the only registered alcohol trial enrolled nine participants.

Magnitude: Across the 27 pooled animal studies, ibogaine significantly reduced drug self-administration, concentrated in the first 24 hours after dosing, while producing no change in conditioned place preference; the registered human alcohol trial (NCT03380728) enrolled nine participants.

Antidepressant Effect Outside Substance Use Disorders

A rapid, ketamine-like antidepressant effect independent of any substance problem is plausible from ibogaine’s NMDA antagonism and growth-factor induction, and a single dose of ibogaine or noribogaine produces antidepressant-like behaviour in rats lasting well beyond drug clearance. In humans this has only been observed as a secondary outcome in populations selected for substance dependence or head injury, where the improvement cannot be separated from resolution of the primary problem. No trial has enrolled people with depression alone.

Magnitude: Not quantified in available studies.

Speculative 🟨

Durable Reset of Entrenched Behavioural Patterns via Neuroplasticity

The broadest claim made for ibogaine among longevity-oriented users is that it opens a period of heightened neural plasticity in which long-standing habits, avoidance patterns and rigid self-narratives become modifiable — an effect framed as a one-time intervention rather than a chronic therapy. The basis is mechanistic and anecdotal: growth-factor induction in animals, structural plasticity demonstrated for the psychedelic class generally, and consistent first-person reports. No controlled study has tested behavioural flexibility as a primary outcome in people without a substance or trauma diagnosis, so this remains an extrapolation from mechanism.

Neuroprotection and Support for Brain Aging

Because ibogaine raises expression of growth factors that maintain dopamine neurons, it has been proposed as a candidate for protecting against age-related decline in dopaminergic function and cognitive resilience. The basis is mechanistic, preclinical and, at most, a single short-term human signal: no study has examined ibogaine in an aging population or in a neurodegenerative disease model relevant to humans, and the only human measurement touching biological aging is the one-month reduction in imaging-predicted brain age in the 30-veteran cohort, an uncontrolled result in young injured brains that says nothing about the trajectory of an uninjured brain over years. The countervailing preclinical evidence of cerebellar cell loss at high doses means the net effect on long-term brain health is not merely unproven but genuinely undetermined in direction.

Benefit-Modifying Factors

CYP2D6 genotype: The enzyme that converts ibogaine to noribogaine varies enormously between people. Poor metabolisers accumulate the parent compound and experience a longer, more intense and more cardiotoxic session at a given dose, while ultrarapid metabolisers may clear it fast enough to blunt both the experience and the effect. Genotype-guided dosing is the single most identified lever for improving the benefit-to-harm ratio.
Baseline magnesium, potassium and QT interval: These are usually treated as safety variables, but they also determine benefit indirectly, because a person with a favourable baseline can be given a full therapeutic dose whereas a person with a borderline QT interval or low potassium must be dose-limited or excluded entirely. Baseline symptom severity matters in the opposite direction: the very large improvements reported in veterans were measured in people starting from severe impairment, and the same absolute change is not available to someone starting near normal.
Sex-based differences: Essentially the entire modern efficacy dataset in head injury is male — the Stanford cohort was 30 of 30 men — while the opioid cohorts have included women in roughly equal proportion. Women have a longer baseline QT interval, which constrains the dose that can be safely given and therefore may cap achievable benefit; no study has been powered to compare response between sexes.
Pre-existing health conditions: People maintained on long-acting opioids, particularly methadone, respond less predictably than those on short-acting opioids and generally require conversion beforehand. Co-existing depression, chronic pain and unresolved trauma appear to predict larger reported improvement, simply because more symptom burden is available to resolve; impaired liver function slows conversion to the active metabolite and alters the entire exposure profile.
Age-related considerations: Older adults in the target range have reduced hepatic clearance, a higher baseline prevalence of conduction abnormalities, and more concurrent medication, all of which push toward lower doses and therefore smaller expected effects. Growth-factor responsiveness also declines with age in animal models, so the neuroplasticity-dependent portion of the benefit may be attenuated in exactly the group most interested in it.
Preparation and integration structure: The reported durability of benefit tracks closely with what happens in the weeks after dosing rather than the dose itself. Programmes that pair the session with structured psychological support report better maintenance of gains than single-session treatment without follow-up, though no trial has randomised this component.

Potential Risks & Side Effects

High 🟥 🟥 🟥

QT Interval Prolongation and Ventricular Arrhythmia

Ibogaine’s defining danger is electrical, not psychological. By blocking the hERG potassium channel, ibogaine and noribogaine delay the electrical reset of heart muscle cells, lengthening the QT interval and creating a window in which the heart can fall into torsades de pointes (a chaotic, twisting ventricular rhythm that can degenerate into cardiac arrest). The evidence is consistent and multi-source: laboratory channel studies, a pharmacokinetic study modelling the concentration-effect relationship in patients, the adverse-event systematic review identifying QT prolongation as the most common acute event, and case reports of arrhythmia at therapeutic doses in people with no prior cardiac history or family history. Because noribogaine persists for days, the risk window extends well beyond the acute experience — a point routinely underestimated by providers who monitor only the first night.

Magnitude: Mean corrected QT interval increases on the order of 30–60 milliseconds follow a 10 mg/kg dose, with individual peaks well beyond the 500-millisecond threshold at which arrhythmia risk rises sharply; hERG blockade occurs at half-maximal inhibitory concentrations of approximately 3.5 micromolar for ibogaine and 2.9 micromolar for noribogaine.

Fatal Outcome

Ibogaine has caused deaths, and the mechanism is understood. Deaths cluster around cardiac arrest during or in the days after the session, with contributing factors including pre-existing cardiovascular disease, concurrent use of other drugs, and seizures during alcohol or benzodiazepine withdrawal. The evidence base is a systematic forensic review of all known fatalities outside West Central Africa between 1990 and 2008, an updated toxicological review, and individual case reports since. Crucially, the fatality record is dominated by unsupervised or minimally supervised settings, and the reviews of clinical studies conducted with screening and continuous monitoring report no comparable pattern — which is informative about mitigability but does not make the underlying hazard smaller.

Magnitude: Nineteen deaths temporally associated with ibogaine were documented between 1990 and 2008, occurring 1.5 to 76 hours after ingestion, and 27 had been reported in the literature by 2016; in 12 of the 14 cases with adequate post-mortem data, advanced pre-existing illness — mainly cardiovascular — or other drugs explained or contributed to the death.

Acute Ataxia, Tremor and Motor Impairment

Ibogaine produces profound ataxia (loss of coordinated movement and balance) during the acute phase, to the point that treated individuals cannot reliably stand or walk unassisted, accompanied by tremor that drug references list alongside ataxia and nausea as one of the three most frequently reported acute effects. The mechanism is cerebellar, consistent with the compound’s effects on the inferior olive-Purkinje cell pathway. The evidence is universal across clinical reports and quantified in pooled animal data showing measurable motor impairment in the first 24 hours after dosing. It is fully reversible in humans at therapeutic doses, but it creates a substantial fall and aspiration hazard, which is why treatment protocols keep people supine and attended.

Magnitude: Motor impairment is near-universal at flood doses and typically persists 24–36 hours, with residual unsteadiness and low-amplitude tremor for a further one to three days; in the pooled animal meta-analysis, motor impairment was statistically significant within the first 24 hours after administration.

Severe Nausea and Vomiting

Nausea begins within the first hour and vomiting is frequent throughout the acute phase. The mechanism is likely combined central and gastrointestinal serotonergic action. Beyond the discomfort, the clinical significance is that vomiting causes fluid and electrolyte loss — particularly potassium and magnesium — in exactly the situation where low levels of those electrolytes amplify the arrhythmia risk, creating a compounding hazard rather than an independent nuisance. This is why clinic protocols routinely include intravenous fluids and antiemetic (anti-nausea) medication chosen to avoid further QT prolongation.

Magnitude: Gastrointestinal effects were among the most frequently reported acute events in the adverse-event systematic review, second in frequency only to cardiac findings, and nausea affects the large majority of treated individuals in published clinical series.

Prolonged and Psychologically Demanding Altered State

The visionary phase is far longer than any other commonly used psychedelic and can be extremely distressing, involving vivid autobiographical review, confrontation with traumatic material, and a period of disorientation on emergence. The evidence is uniform across clinical and ethnographic reports and quantified in a recently developed instrument for measuring the experience. Unlike shorter-acting compounds, the duration removes the option of waiting it out — once dosed, a person is committed for a day or more, and psychological support cannot be reduced without materially increasing risk.

Magnitude: Effects begin 30 minutes to three hours after ingestion, peak over roughly the first four to eight hours, and continue as an acute phase lasting 24–36 hours in total, with residual effects for a further 24–72 hours — roughly four to eight times the duration of psilocybin (four to six hours) and two to four times that of lysergic acid diethylamide (eight to twelve hours).

Medium 🟥 🟥

Bradycardia and Hypotension

Alongside QT prolongation, ibogaine slows the heart rate and lowers blood pressure during the acute phase, an effect attributed to its actions on cardiac ion channels and autonomic tone. The evidence is clinical observation in monitored settings and case reports. It is usually self-limiting and clinically manageable, but bradycardia (an abnormally slow heart rate) itself further prolongs the QT interval, so the two effects reinforce each other rather than acting independently — the reason continuous rather than intermittent monitoring is specified in the safety literature.

Magnitude: Heart rates in the 40–50 beats-per-minute range are commonly recorded during the acute phase in monitored clinical settings, compared with a typical resting range of 60–80.

Loss of Opioid Tolerance and Elevated Overdose Risk on Relapse

This risk is often overlooked because it materialises after the person has left the clinic feeling well. Any effective opioid detoxification resets tolerance, so a return to the pre-treatment dose can be lethal; ibogaine does this faster and more completely than a gradual taper, and it does so in people who frequently believe their craving has been permanently removed. The evidence is the general opioid-detoxification literature on post-detoxification overdose mortality combined with case reports following ibogaine specifically. It is entirely preventable with counselling and take-home naloxone, and entirely lethal without.

Magnitude: Overdose mortality in the weeks following any opioid detoxification is several-fold higher than during ongoing maintenance treatment; ibogaine produces the same tolerance reset within a single session rather than over a taper.

Post-Treatment Insomnia and Fatigue

A period of disrupted sleep and pronounced fatigue routinely follows the acute phase, attributed to the persistence of noribogaine and to the stimulant character of the compound at low residual concentrations. The evidence is consistent clinical reporting across cohorts. It is self-limiting but not trivial for someone optimising recovery and cognitive performance, and it is the main reason treatment programmes build in several days of low-demand time rather than releasing people immediately.

Magnitude: Sleep disruption commonly persists for three to seven nights after dosing, with fatigue reported for one to two weeks — consistent with the 28–49 hour half-life of the active metabolite and its slow redistribution from fat tissue.

Low 🟥

Seizures

Seizures have been reported in association with ibogaine, but the fatality review found they clustered in people withdrawing from alcohol or benzodiazepines rather than opioids, implicating the withdrawal state rather than ibogaine itself as the proximate cause. The evidence is case reports and the forensic case series. Severity is high when it occurs, but the at-risk population is narrow and identifiable in advance through a medication and alcohol history, which makes this one of the more tractable risks.

Magnitude: Not quantified in available studies.

Persistent Psychiatric Complications

Case reports describe prolonged psychosis, mania and persistent perceptual disturbance following ibogaine, as with the psychedelic class generally. The mechanism is presumed to be destabilisation of latent vulnerability rather than a specific toxic effect. The evidence base is isolated reports and screening exclusions in clinical protocols rather than incidence data; the risk is concentrated in people with a personal or family history of psychotic or bipolar illness, which is why every published clinical protocol screens for it. Duration ranges from days to, in a minority of reports, months.

Magnitude: Not quantified in available studies.

Cerebellar Neurotoxicity ⚠️ Conflicted

The most contested harm in the ibogaine literature is whether it damages the cerebellum. Rats given very high doses show degeneration of Purkinje cells, and pooled animal data confirm cerebellar cell loss detectable weeks after administration; the counter-evidence is that the effect is strongly dose-dependent, absent at doses at or below 25 mg/kg, not reproduced in primates at human therapeutic doses, and unaccompanied by any characteristic neurotoxic syndrome in the human forensic case series. Both bodies of evidence are real and neither has been resolved by a study designed to settle the question in humans.

Magnitude: Purkinje cell degeneration appears in rats at 100 mg/kg administered into the abdominal cavity but has not been observed at doses at or below 25 mg/kg — a threshold above the 10–20 mg/kg range used in humans, though route and species differences make the comparison imperfect.

Hepatic Enzyme Elevation

Isolated reports describe transient elevation of liver enzymes following ibogaine, plausible given the compound’s extensive hepatic metabolism and high tissue loading. The evidence is case-level only, with no cohort data on incidence. It appears reversible and has not been associated with liver failure in the published record, but it is a reason to establish liver function before dosing rather than after.

Magnitude: Case reports describe alanine aminotransferase and aspartate aminotransferase (two liver enzymes released when liver cells are stressed) rising to several times the upper limit of normal and returning to baseline within weeks.

Speculative 🟨

Cumulative Cardiac Risk with Repeated Dosing

Whether repeated ibogaine sessions — booster doses days later, or repeat treatments months apart — produce cumulative rather than merely repeated cardiac risk is unknown. The concern is mechanistic: the very large volume of distribution and slow release from fat tissue mean a second dose may be superimposed on residual metabolite, and no study has measured tissue loading across repeat administrations. No controlled data exist in either direction; the basis for the concern is pharmacokinetic reasoning alone.

Unknown Effects on Long-Term Neurodegenerative Risk

The same growth-factor induction proposed as a neuroprotective benefit could in principle carry long-term costs, and the preclinical cerebellar findings raise the question of whether subclinical cell loss accumulates. No human study has followed ibogaine-treated individuals for more than 12 months, and none has used imaging or fluid biomarkers of neurodegeneration. The basis here is mechanistic and inferential only, with no controlled or observational data on either side.

Risk-Modifying Factors

CYP2D6 genotype: Poor metabolisers of this enzyme clear ibogaine far more slowly, reaching higher parent-compound concentrations and correspondingly greater QT prolongation from the same milligram-per-kilogram dose. This is the best-characterised risk modifier in the literature and the one most explicitly recommended for pre-treatment genotyping.
Congenital and acquired long QT susceptibility: Variants in KCNQ1, KCNH2 and SCN5A (the genes encoding the potassium and sodium channels that shape the heart’s electrical recovery) underlie congenital long QT syndrome and convert an ordinary dose into a lethal one. A personal history of unexplained fainting or a family history of sudden cardiac death before age 50 is a practical proxy where genetic testing is unavailable.
Baseline electrolytes and QT interval: Low potassium (hypokalemia, below roughly 3.8 mmol/L), low magnesium (hypomagnesemia) and low ionised calcium each independently lengthen the QT interval and are additive with ibogaine’s effect. A baseline corrected QT interval already above 450 milliseconds in men or 460 in women leaves no electrical margin, and diuretic use, vomiting, diarrhoea or restrictive eating in the preceding weeks are common causes of an unrecognised deficit.
Sex-based differences: Women have a longer baseline corrected QT interval than men and a well-documented higher incidence of drug-induced torsades de pointes across all QT-prolonging medications, so an identical dose carries a higher arrhythmic risk. Against this, essentially all published head-injury efficacy data are from men, so women face a less favourable risk-to-evidence position on both sides of the equation.
Pre-existing health conditions: Structural heart disease, heart failure, coronary artery disease, recent myocardial infarction and any conduction abnormality all multiply the cardiac hazard. Liver impairment alters the ratio of parent compound to metabolite unpredictably; kidney impairment slows elimination of the glucuronide metabolite; a history of psychotic or bipolar illness governs the psychiatric risk; and active alcohol or benzodiazepine dependence introduces the seizure risk that dominated part of the fatality series.
Age-related considerations: Cardiac conduction slows and the QT interval lengthens with age, the prevalence of undiagnosed structural heart disease rises steeply after 50, and the use of several medications at once — particularly antidepressants, antibiotics and antiarrhythmics — increases the chance of an unrecognised additive interaction. For someone at the older end of a health-optimising cohort, the same protocol that is relatively low-risk at 30 is materially riskier at 60, and pre-treatment cardiac imaging rather than an electrocardiogram alone becomes the reasonable baseline.

Key Interactions & Contraindications

Other QT-prolonging prescription medications: Absolute contraindication without washout. Combining ibogaine with antiarrhythmics (amiodarone, sotalol, quinidine), macrolide antibiotics (a common infection-treating class including azithromycin and clarithromycin), fluoroquinolones (a broad-spectrum antibiotic class including levofloxacin and moxifloxacin), antipsychotics (haloperidol, ziprasidone, quetiapine), the antiemetic ondansetron, or QT-prolonging antidepressants (citalopram, escitalopram, and the tricyclic class, an older group of antidepressants such as amitriptyline) produces additive lengthening of the QT interval and a sharply elevated risk of torsades de pointes. Mitigation is discontinuation for at least five elimination half-lives of the interacting drug, with a repeat electrocardiogram confirming return to baseline before dosing.
Methadone and long-acting opioids: Absolute contraindication in the maintenance state. Methadone independently prolongs the QT interval and has a half-life long enough that it remains present through the ibogaine session, compounding both cardiac risk and an unpredictable withdrawal course. Mitigation is medically supervised conversion to a short-acting opioid over one to two weeks before treatment, an approach used in the registered methadone-detoxification study.
CYP2D6 inhibitors: Caution to absolute contraindication depending on potency. Paroxetine, fluoxetine, bupropion, duloxetine, quinidine and terbinafine block the enzyme that clears ibogaine, converting a normal metaboliser into a functional poor metaboliser and raising exposure several-fold with a proportionate increase in cardiac risk. Fluoxetine requires a particularly long washout — at least five weeks — because of its own extended half-life and that of its active metabolite.
Serotonergic medications: Absolute contraindication for monoamine oxidase inhibitors (an older antidepressant class that blocks the enzyme breaking down serotonin; phenelzine, tranylcypromine, selegiline, moclobemide), caution for selective serotonin reuptake inhibitors (SSRIs, the most commonly prescribed antidepressant class, which raise serotonin by blocking its reabsorption; sertraline, fluoxetine, paroxetine, citalopram) and serotonin-norepinephrine reuptake inhibitors (a related class that also raises noradrenaline; venlafaxine, duloxetine, desvenlafaxine). The clinical consequence is serotonin toxicity — agitation, rigidity, hyperthermia and, at the severe end, cardiovascular collapse. Mitigation is full discontinuation under medical supervision with an appropriate washout period.
Benzodiazepines and alcohol: Caution, and absolute contraindication in the withdrawal state. Ibogaine does not prevent benzodiazepine or alcohol withdrawal, and seizures during that withdrawal were an identified contributor in the fatality series. Mitigation is stabilisation and a completed, medically supervised taper well before ibogaine is considered, never a simultaneous attempt at both.
Over-the-counter medications: Caution. Diphenhydramine and doxylamine (sedating antihistamines) prolong the QT interval and add anticholinergic burden; loperamide, widely self-administered at high doses for opioid withdrawal, is a potent QT-prolonging agent in its own right and a documented cause of arrhythmia; dextromethorphan is both a CYP2D6 substrate and serotonergic; cimetidine inhibits several drug-metabolising enzymes. Mitigation is a complete over-the-counter medication and cold-remedy inventory during screening, not just a prescription list.
Supplement interactions: Caution to absolute contraindication. St. John’s wort is both serotonergic and a strong inducer of CYP3A4, altering exposure unpredictably; 5-HTP (5-hydroxytryptophan, a direct precursor the body converts into serotonin), L-Tryptophan and S-adenosylmethionine add serotonergic load; berberine blocks the hERG channel and adds directly to the arrhythmia risk; high-dose liquorice root causes potassium loss; yohimbine and high-dose stimulant preparations including concentrated caffeine raise sympathetic tone during a period of unstable cardiac electrophysiology; grapefruit extract inhibits CYP3A4. Mitigation is a two-week supplement washout apart from those deliberately used for cardiac protection.
Supplements with additive effects on the intervention: Monitor rather than avoid; the clinical consequence is a shortened QT interval and a raised threshold for arrhythmia. Magnesium is the clearest example and the interaction is deliberately exploited rather than avoided — intravenous magnesium shortens the QT interval and stabilises cardiac membranes, and it was co-administered as the central safety element of the Stanford protocol. Potassium repletion works in the same direction. Both are additive with ibogaine’s cardiac effect in the protective sense, but oral supplementation alone does not reliably correct a deficit inside cells, which is why the intravenous route is used in monitored settings.
Interactions with other interventions: Caution. Concurrent or sequential 5-MeO-DMT, as used in several veteran cohorts, confounds both benefit and risk attribution and adds cardiovascular load; ketamine shares NMDA antagonism and adds sedation; kratom is opioid-active and QT-prolonging; and any fasting, ketogenic or aggressive diuretic protocol undertaken in the preceding week can produce the electrolyte depletion that converts a manageable QT change into a dangerous one. Mitigation is to separate any other psychoactive intervention from the ibogaine session by at least one full clearance interval rather than combining them, to discontinue kratom for at least two weeks with a confirmatory electrocardiogram, and to suspend fasting, ketogenic and diuretic protocols for two weeks before dosing with documented electrolyte repletion.
Populations who should avoid this intervention: Absolute exclusions in published protocols are congenital long QT syndrome or a family history of sudden cardiac death before age 50; a baseline corrected QT interval above 450 milliseconds in men or 460 in women; structural heart disease, heart failure of New York Heart Association Class III or IV (marked limitation of activity, or symptoms at rest), coronary artery disease, or myocardial infarction within the previous six months; uncorrected potassium below 3.8 mmol/L or magnesium below 0.75 mmol/L; liver impairment of Child-Pugh Class B or C (moderate or severe cirrhosis on the standard severity score); severe kidney impairment with estimated glomerular filtration rate below 30 mL/min/1.73 m²; a personal or first-degree family history of schizophrenia, other psychotic illness or bipolar I disorder; active seizure disorder; current alcohol or benzodiazepine dependence; pregnancy or breastfeeding; and current methadone or buprenorphine maintenance without prior conversion.

Risk Mitigation Strategies

CYP2D6 genotyping before dosing: Testing metaboliser status and reducing the dose in poor metabolisers directly addresses the largest identified source of unpredictable exposure and therefore of QT prolongation. The pharmacokinetic literature explicitly recommends genotype-guided rather than weight-only dosing; in practice this means reducing from the standard 10–15 mg/kg toward the lower end or excluding poor metabolisers entirely.
Comprehensive cardiac screening: A 12-lead electrocardiogram with manually verified corrected QT interval, an echocardiogram to exclude structural disease, and a personal and family cardiac history covering unexplained syncope (fainting from a temporary loss of blood flow to the brain) and premature sudden death together identify almost every individual in whom the arrhythmia risk is unacceptable. This is the specific intervention that separates the fatality record of unsupervised use from the safety record of screened clinical studies.
Electrolyte optimisation and magnesium co-administration: Correcting potassium to at least 4.0 mmol/L and magnesium to at least 0.85 mmol/L before dosing, then administering intravenous magnesium during the session, shortens the QT interval and raises the threshold for the ventricular arrhythmia that is ibogaine’s principal cause of death. This is the defining feature of the Stanford protocol, under which no unexpected or serious adverse events were reported in 30 participants.
Continuous cardiac telemetry for at least 48–72 hours: Because noribogaine persists with a half-life of 28–49 hours, arrhythmias have occurred days after dosing, so monitoring limited to the acute experience misses part of the risk window. Continuous rhythm monitoring with immediate access to defibrillation and intravenous magnesium for the first 48 hours minimum, with a repeat electrocardiogram at 72 hours and one week, addresses the delayed component of the cardiac hazard.
Staged dosing with a test dose: Administering a 100 mg test dose and observing for one to three hours before the main dose identifies idiosyncratic sensitivity and early QT change before full exposure is committed. This mitigates the irreversibility problem created by the compound’s 24–36 hour duration, during which a dose cannot be withdrawn once given.
Structured medication washout: Discontinuing all QT-prolonging drugs, CYP2D6 inhibitors and serotonergic agents for at least five elimination half-lives — extending to five weeks for fluoxetine — with a confirmatory electrocardiogram before dosing prevents the additive QT prolongation and serotonin toxicity that account for a substantial share of reported serious adverse events.
Conversion from long-acting to short-acting opioids: Transitioning off methadone over one to two weeks before treatment removes both an independent QT-prolonging agent and the prolonged, unpredictable withdrawal course that makes ibogaine less effective and more dangerous in maintenance patients.
Antiemetic support and intravenous fluid maintenance: Preventive antiemetic medication selected to avoid further QT prolongation, combined with maintenance intravenous fluids, prevents the vomiting-driven potassium and magnesium loss that compounds arrhythmia risk during the acute phase.
Post-treatment overdose prevention: Explicit counselling that opioid tolerance has been reset, together with take-home naloxone and a defined aftercare contact for the first 90 days, addresses the delayed and easily overlooked risk of fatal overdose on relapse — a risk that is at its highest precisely when the person feels most confident.
Psychiatric screening and integration support: Excluding personal and first-degree family history of psychotic and bipolar illness prevents the prolonged psychiatric complications reported in case series, while scheduled psychological follow-up in the weeks after dosing addresses both the distress of the acute experience and the durability of any behavioural change.

Therapeutic Protocol

Standard single flood dose: The dominant approach among established providers is a single oral dose of purified ibogaine hydrochloride at 10–20 mg/kg body weight, with most contemporary clinics working in the 10–15 mg/kg range and academic protocols at the lower end. Howard Lotsof’s original patents specified doses in this range, Deborah Mash’s St. Kitts programme used approximately 8–12 mg/kg, and the Stanford magnesium-ibogaine protocol under Nolan Williams used a comparable dose paired with intravenous magnesium.
Competing therapeutic approaches: Three distinct approaches coexist without a clear winner. The flood-dose model, associated with Lotsof and the Mexican and Caribbean clinics, treats the intense single session as the therapeutic agent. A low-dose or repeated-microdose model, used by a minority of practitioners at roughly 0.5–2 mg/kg or fixed doses in the tens of milligrams, aims at craving reduction and mood effects without the visionary state and without the full cardiac exposure — it has essentially no controlled evidence behind it. A third approach uses total alkaloid extract, containing the full complement of iboga alkaloids rather than purified ibogaine, favoured in Bwiti-derived and provider traditions on the argument that the alkaloid mixture is better tolerated; potency is far less predictable. Neither the flood-dose nor the low-dose model has been tested against the other.
Named clinical programmes: Deborah Mash’s University of Miami and St. Kitts programme established the modern medical protocol; Nolan Williams’s Stanford group developed the magnesium co-administration protocol; Ambio Life Sciences in Mexico, associated with Trevor Millar, provided treatment for the published veteran cohort; Clare Wilkins and Martín Polanco ran early Mexican clinical programmes that generated much of the informal dosing knowledge. Each of these parties has either a commercial or a research-programme interest in ibogaine’s continued use, which is relevant when protocols originate from them rather than from independent trials.
Timing within the day: Dosing is conventionally done in the early morning after an overnight fast of 8–12 hours, so that the peak visionary phase in the first four to eight hours and the highest-risk cardiac window fall within periods of full staffing rather than overnight, and so that gastric emptying reduces the vomiting that follows a fed-state dose.
Half-life and its protocol consequences: Ibogaine’s own half-life of roughly four to eight hours is misleadingly short. The active metabolite noribogaine has a mean half-life of 28–49 hours and a very large volume of distribution, so exposure and cardiac risk extend for days after the subjective experience ends — which is why protocols specify multi-day monitoring rather than overnight observation.
Single versus split dosing: The prevailing practice is a single main dose, usually preceded by a 100 mg test dose one to three hours earlier to detect idiosyncratic sensitivity. Some providers add a small booster dose of 1–3 mg/kg on a subsequent day for people whose withdrawal symptoms return; because noribogaine is still present at that point, boosters superimpose exposure rather than replacing it and are a period of elevated rather than reduced cardiac risk.
Genetic polymorphisms influencing dose: CYP2D6 metaboliser status is the dominant pharmacogenetic variable and the one for which genotype-guided dosing has been explicitly recommended in the pharmacokinetic literature. Variants in KCNQ1, KCNH2 and SCN5A determine whether any dose is acceptable at all rather than how much; where genotyping is unavailable, a detailed family cardiac history serves as an imperfect substitute.
Sex-based differences in dosing: The longer baseline QT interval in women and their higher incidence of drug-induced torsades de pointes argue for dosing at the lower end of the range and for a stricter baseline QT cut-off, though no trial has formally compared dose-response between sexes and the head-injury efficacy data derive entirely from male cohorts.
Age-related considerations: Reduced hepatic clearance, age-related QT lengthening and the rising prevalence of undiagnosed structural heart disease after 50 all argue for lower doses, echocardiographic rather than electrocardiographic screening alone, and longer monitoring in older participants. No published protocol specifies an upper age limit, but the published cohorts skew heavily toward people in their 30s and 40s, so the evidence supporting any dose in a 65-year-old is extrapolated rather than direct.
Baseline biomarkers influencing dosing: Serum potassium, magnesium and ionised calcium, the corrected QT interval, and liver and kidney function together determine both whether a full dose is permissible and how quickly the compound will be cleared. Protocols repeat electrolyte measurement on the morning of dosing rather than relying on screening bloodwork taken weeks earlier.
Pre-existing conditions influencing response: Long-acting opioid maintenance, chronic pain requiring ongoing opioid therapy, significant depression, and unresolved trauma each change both the expected response and the aftercare required. Providers routinely stage treatment behind conversion from methadone and behind stabilisation of any psychiatric instability, on the basis that response in unstabilised patients is both weaker and less predictable.

Discontinuation & Cycling

Single-session rather than lifelong use: Ibogaine is not a chronic medication. The prevailing model is one session, occasionally followed by a small booster within days, with the therapeutic effect expected to come from a discrete change rather than from ongoing exposure — the opposite of the maintenance model used for opioid substitution therapy.
Absence of withdrawal from ibogaine itself: Ibogaine produces no physical dependence and is not self-reinforcing in animal models; discontinuation after a single session causes no withdrawal syndrome. What does occur in the days afterwards — insomnia, fatigue, emotional lability (rapid, poorly controlled swings in mood) — reflects the residual metabolite and the intensity of the experience rather than a withdrawal state.
Tapering of prior medications: No taper of ibogaine is required or possible. The tapering that matters is of everything else: supervised conversion off methadone, discontinuation of serotonergic and QT-prolonging medications across the appropriate washout, and a completed benzodiazepine or alcohol taper before the session. Attempting ibogaine while any of these tapers is incomplete is where much of the documented harm has occurred.
Repeat treatment and cycling intervals: There is no evidence-based cycling schedule. Clinic practice generally holds that repeat flood-dose treatment should not occur sooner than three to six months, on the grounds that the fat-tissue reservoir and any cardiac effect need time to clear and that the therapeutic window from a single dose is measured in months rather than weeks. Whether repeat dosing sustains benefit, produces diminishing returns, or accumulates risk has not been studied in any controlled setting.
Managing the return of craving: Where craving returns — commonly reported at the two-to-three-month mark in observational cohorts — the practical options are behavioural and pharmacological support rather than immediate re-dosing, given that the risk profile of repeat administration is uncharacterised while the risk profile of conventional relapse-prevention treatment is well understood.

Sourcing and Quality

Form and potency: Three materials circulate under the same name and they are not interchangeable. Purified ibogaine hydrochloride is the only form with predictable potency and the form used in every clinical study. Total alkaloid extract contains ibogaine plus related alkaloids at variable ratios. Raw root bark varies in ibogaine content by an order of magnitude between samples and harvests, which makes weight-based dosing meaningless and has contributed to fatalities involving ethnopharmacological preparations.
Purity verification: A certificate of analysis from an independent laboratory, showing assay by high-performance liquid chromatography (a standard laboratory method for separating and quantifying the components of a mixture) with results for ibogaine content, related alkaloid profile, residual solvents and heavy metals, is the minimum meaningful documentation. Material without an assay result is of unquantified strength, which matters for a compound where a two-fold dosing error is potentially fatal.
Manufacturing standard: Pharmaceutical-grade material produced under good manufacturing practice (a regulated quality standard governing pharmaceutical production) is available to research programmes and to some licensed clinics; the material used in most clinic settings is not. Semi-synthesis from voacangine, an alkaloid obtained from Voacanga africana, gives more consistent purity than extraction from iboga root bark and is the preferred production route.
Which sources can actually be named: No consumer brand of ibogaine exists and no compounding pharmacy supplies it, because the compound is not lawfully sold as a supplement or a compoundable prescription ingredient in most jurisdictions — so the usual brand-comparison exercise does not apply, and any vendor presenting itself as a consumer brand is by definition operating outside regulation. The reputable material that can be named is pharmaceutical-grade ibogaine hydrochloride made for registered development programmes: DemeRx IB and its parent atai Therapeutics produced the good-manufacturing-practice material (DMX-1002) used in the completed Phase 1/2 study, and comparable pharmaceutical-grade material was used in Deborah Mash’s University of Miami and St. Kitts programme and in Nolan Williams’s Stanford protocol. Outside those channels, an independent certificate of analysis is the only remaining evidence of quality, and Health Canada’s seizure of the ibogaine products sold as Remogen, Endabuse and Iboga illustrates what unlicensed supply looks like in practice.
Avoiding online purchase: Internet-sourced ibogaine has produced documented cases of prolonged multiple cardiac arrhythmias, and it carries the combined problems of unverifiable content, no screening, and no monitoring. This is the single most consequential sourcing decision in the entire topic, because the compound’s danger is dose-dependent and self-administration removes every protective element that separates the clinical safety record from the fatality record.
Conservation and ethical sourcing: Tabernanthe iboga is slow-growing and has been heavily overharvested; Gabon regulates its export and treats it as a national heritage plant. Semi-synthetic material from Voacanga africana, a faster-growing and more abundant source, avoids pressure on wild iboga populations, and providers able to document their supply chain are preferable on both quality and conservation grounds.

Practical Considerations

Time to effect: Effects on opioid withdrawal are essentially immediate, within the first 24–48 hours. Craving reduction is apparent within days. The mood, trauma and cognitive changes reported in veteran cohorts were measured immediately after treatment and again at one month, with the larger effects at one month — implying that the full benefit is not apparent on leaving the clinic and that judging the outcome too early understates it.
Common pitfalls: The recurring errors are dosing without a cardiac workup or electrolyte correction; incomplete disclosure of prescription, over-the-counter and supplement use, particularly antidepressants; attempting treatment during benzodiazepine or alcohol withdrawal; treating from methadone maintenance without conversion; purchasing material online for self-administration; monitoring only the first night despite the metabolite’s multi-day persistence; and returning to a previous opioid dose after tolerance has been reset. Treating the session as the whole intervention and skipping structured follow-up is the most common reason reported benefits fail to persist.
Regulatory status: Ibogaine is a Schedule I controlled substance in the United States, so all domestic use outside an approved research protocol is unlawful, and clinics operate abroad. Its status elsewhere varies: it is unscheduled in Mexico and Costa Rica, where most treatment clinics are located; regulated as a prescription non-approved medicine in New Zealand; unscheduled but not approved in Canada; and controlled in most of Western Europe. Two developments are changing this — Texas committed $50 million in 2025 through Senate Bill 2308, signed into law on 11 June 2025, to fund clinical trials aimed at eventual regulatory approval, and multiple registered trials are now running in academic settings.
Cost and accessibility: Treatment is exceptionally expensive and geographically restricted. Clinic programmes typically run several thousand to more than fifteen thousand United States dollars for a five-to-ten-day stay, excluding international travel, and are paid entirely out of pocket since no insurer covers an unapproved indication with a Schedule I compound. This cost structure has a second-order consequence worth naming: it selects for a wealthier, more motivated population in every observational cohort, which is one plausible contributor to the unusually large effect sizes reported.
Payer economics and structural bias: The comparator matters financially as well as clinically. Opioid substitution therapy is a recurring, reimbursed expense that generates continuing revenue for maintenance-treatment providers and dispensing pharmacies and continuing outlay for insurers and national health systems, whereas a single ibogaine session is a one-time cost that no payer currently carries. That asymmetry cuts in both directions and is worth holding in view when reading the literature: institutional payers have an evident interest in a one-time treatment that would end recurring maintenance spending, while the established maintenance sector — which supplies much of the clinical expertise informing addiction-medicine guidelines and research priorities — has the opposite interest. Neither incentive has been examined empirically, but both are plausible sources of structural bias in guideline formation and in which questions attract research funding.

Interaction with Foundational Habits

Sleep: Direct and blunting during and after the session. The acute phase eliminates sleep entirely for 24–36 hours, and the persistence of noribogaine produces fragmented sleep and difficulty initiating sleep for a further three to seven nights, with fatigue extending one to two weeks. The practical considerations are protecting a low-demand recovery period rather than returning immediately to work or training, and avoiding sedating antihistamines as a sleep aid during this window because they prolong the QT interval at exactly the wrong time.
Nutrition: Direct and bidirectional. An 8–12 hour overnight fast before dosing reduces vomiting; conversely, any recent period of restrictive eating, aggressive fasting, ketogenic transition or heavy diuretic use depletes potassium and magnesium and materially raises arrhythmia risk, so clinic protocols direct nutritional preparation toward electrolyte repletion rather than restriction in the preceding two weeks. Grapefruit and St. John’s wort alter drug-metabolising enzyme activity and are excluded under those protocols. After treatment, nausea and appetite suppression can persist for several days, making structured rehydration and gradual refeeding more relevant than any particular dietary pattern.
Exercise: Indirect and blunting in the short term. Strenuous exercise in the days before dosing causes sweat-mediated electrolyte loss that compounds the cardiac risk, and exercise during the acute and immediate post-acute phase is precluded by ataxia and cardiovascular instability. The practical consideration is a taper of training load in the week before, no training during the monitoring window, and a graded return over one to two weeks once fatigue resolves and a follow-up electrocardiogram confirms return to baseline.
Stress management: Direct and potentiating in both directions. The prolonged visionary state is itself an intense psychological stressor involving confrontation with autobiographical and traumatic material, so entering it without an established regulation practice increases the likelihood of a distressing experience. Conversely, the reported durability of benefit tracks with what happens afterwards: structured integration, meditation or therapy in the following weeks is the component most consistently associated with maintained gains, and the human data showing that the intensity of the mystical-type experience predicts symptom improvement suggest that psychological preparation is not peripheral to the pharmacology but part of the intervention.

Monitoring Protocol & Defining Success

Baseline testing before any ibogaine exposure is not optional supporting information but the mechanism by which the intervention’s principal fatal risk is screened out; published protocols complete the panel below within 30 days of dosing and repeat electrolytes and an electrocardiogram on the morning of administration.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Corrected QT interval (QTc) on 12-lead electrocardiogram	<430 ms (men), <440 ms (women)	Direct measure of the electrical window in which fatal arrhythmia occurs	Conventional upper limits are 450 ms (men) and 470 ms (women); the tighter functional target preserves margin for a 30–60 ms drug-induced increase. Manual verification required — automated readings are unreliable at slow heart rates
Serum potassium	4.0–4.5 mmol/L	Low potassium lengthens the QT interval and is additive with ibogaine’s effect	Conventional reference range extends down to 3.5 mmol/L, which is inadequate here. Recent vomiting, diarrhoea, diuretic use or restrictive eating are common causes of an unrecognised deficit; avoid a tourniquet-induced false elevation
Serum magnesium and red blood cell magnesium	Serum 0.85–1.05 mmol/L; red cell magnesium in the upper half of the laboratory range	Magnesium stabilises cardiac membranes and is the basis of the protective co-administration protocol	Conventional serum range starts at 0.70 mmol/L; serum reflects only about 1% of body magnesium, so red cell magnesium is the more informative test where available
Ionised calcium	1.18–1.30 mmol/L	Low ionised calcium independently prolongs the QT interval	Preferred over total calcium, which is confounded by albumin. Draw with minimal stasis; sample handling errors are common
Alanine aminotransferase and aspartate aminotransferase	<25 U/L (men), <20 U/L (women)	Liver enzymes released when liver cells are stressed; hepatic function governs conversion of ibogaine to its active metabolite	Conventional upper limits near 40 U/L are set from populations including undiagnosed fatty liver and are too permissive for a compound with heavy hepatic metabolism. Fasting draw preferred
Estimated glomerular filtration rate (eGFR)	>90 mL/min/1.73 m²	Kidney filtration capacity; governs elimination of the glucuronide metabolite	Conventional threshold for concern is 60 mL/min/1.73 m². Pair with cystatin C in people with high muscle mass, where creatinine-based estimates understate function
CYP2D6 genotype and predicted metaboliser status	Normal (extensive) metaboliser	Determines clearance of ibogaine and therefore peak exposure and cardiac risk	Not a range but a classification; poor metabolisers require dose reduction or exclusion. Single test, valid for life; must be interpreted alongside current CYP2D6-inhibiting medications, which produce the same phenotype
Thyroid-stimulating hormone (TSH)	0.5–2.0 mIU/L	Both underactive and overactive thyroid states alter cardiac conduction and QT interval	Conventional range extends to 4.0–4.5 mIU/L. Morning fasting draw; pair with free thyroxine where the result is outside the functional range
Complete blood count with haemoglobin and haematocrit	Haemoglobin 13.5–15.5 g/dL (men), 12.5–14.5 g/dL (women)	Anaemia reduces tolerance of the bradycardia and hypotension seen during the acute phase	Conventional lower limits are around 13.5 and 12.0 g/dL. Pair with ferritin where low, since iron deficiency without anaemia is common in this population
Echocardiogram (structural assessment)	Normal chamber dimensions and ejection fraction >55%	Detects the structural heart disease that converts a manageable arrhythmia risk into a lethal one	Not a blood test but part of the baseline panel; particularly important above age 50 and in anyone with a history of hypertension, endurance sport, or unexplained fainting

Ongoing monitoring follows a front-loaded cadence dictated by the metabolite’s persistence: continuous cardiac telemetry from dosing through at least 48 hours, a 12-lead electrocardiogram with electrolytes at 24 hours, 72 hours and one week, liver and kidney function at four weeks, and a repeat electrocardiogram plus full baseline panel at three months and again at six to twelve months if any abnormality was detected or if repeat treatment is contemplated.

Qualitative markers matter as much as laboratory values for judging whether the intervention achieved anything, and are best tracked on a fixed schedule at one week, one month, three months and six months:

Craving intensity and frequency: rated on a simple daily scale, since the central claim is a durable reduction rather than acute suppression
Sleep quality and continuity: expected to be disrupted for the first week and to return to or exceed baseline thereafter; failure to normalise by four weeks is a signal worth investigating
Cognitive clarity: subjective processing speed, word-finding and sustained concentration, ideally anchored to a repeatable brief cognitive test rather than impression alone
Emotional reactivity and mood stability: the tendency toward irritability, emotional flatness or intrusive recollection, tracked as a proxy for the trauma-related outcomes measured formally in the veteran cohorts
Motivation and anhedonia (a reduced ability to feel pleasure): willingness to initiate effortful activity and capacity to take pleasure in ordinary rewards, which the growth-factor mechanism predicts should improve if the intervention works as proposed
Behavioural flexibility in daily life: whether long-standing avoidance patterns and habits have actually changed, which is the outcome the neuroplasticity account claims and the one least captured by any laboratory measure

Emerging Research

State-funded clinical development in Texas: In 2025 Texas committed $50 million through Senate Bill 2308 to fund ibogaine clinical trials, with the award made to the University of Texas Medical Branch and UTHealth Houston for a two-year multicentre programme in substance dependence and associated conditions, and parallel work at UT Austin and Baylor College of Medicine on brain injury in veterans. No registry identifier has been posted for these trials yet. This is the largest publicly funded psychedelic research commitment made by any government and is the single development most likely to determine whether ibogaine reaches regulatory approval; it is worth noting that the initiative was actively lobbied for by veterans’ advocacy organisations and by parties with commercial interests in ibogaine treatment.
Magnesium-ibogaine in veterans with blast exposure: NCT04313712, run by Stanford University with 30 participants and disability score as the primary endpoint, is the registered trial behind the published veteran findings and remains active but not recruiting. Its follow-on analyses have continued to appear, including work showing that the intensity of the mystical-type experience predicts trauma symptom improvement (Brown et al., 2026).
Neuroimaging of ibogaine’s effect on reward circuitry: NCT07226570, a University of California, Irvine study recruiting 20 participants with opioid use disorder, uses functional magnetic resonance imaging (a scan measuring blood-flow changes as a proxy for brain activity) and magnetic resonance spectroscopy (which measures brain chemical concentrations) to test whether ibogaine changes connectivity in reward circuits and glutamate levels in the nucleus accumbens and insula. This is the first study designed to test the proposed mechanism directly rather than infer it from symptom change.
Pharmaceutical development and its stalling: NCT05029401, a completed Phase 1/2 study of oral ibogaine in opioid withdrawal with 116 participants sponsored by atai Therapeutics, represents the most advanced commercial programme. The compound has since been largely absent from the sponsor’s pipeline communications, which is itself evidence about how the cardiac risk and Schedule I status weigh against commercial development — a counterweight to the optimism of the academic programmes.
Completed academic trials: NCT04003948, a completed Phase 2 study of ibogaine for methadone detoxification with 20 participants run by the International Center for Ethnobotanical Education, Research, and Service, has not yet published its results and will materially expand the controlled human dataset when it does. The companion alcohol study NCT03380728 has since reported (Rocha et al., 2026): in nine participants given escalating oral doses up to 400 mg, five showed transient QT interval prolongation or shortening, no serious adverse events occurred, most participants reported reduced alcohol use, and only five completed the study — an outcome the authors themselves attribute as plausibly to motivation and placebo effects as to the drug. Both sponsors are organisations whose research mission is oriented toward establishing psychedelic therapies, a consideration in weighing their reported outcomes.
Combination protocols under study: NCT07717866, an active study of 52 participants run by Axial Therapeutic Research examining trauma symptoms, cognitive dysfunction and suicidal ideation, continues the ibogaine-plus-5-MeO-DMT model used in the veteran cohorts. The same protocol was originally registered by Johns Hopkins (NCT06810765) and withdrawn there without enrolling anyone, with the registry recording that the study is instead being conducted externally — a reminder that this line of work is running through commercial sponsors rather than academic centres, which shapes who controls the resulting data.
Non-cardiotoxic analogues as the decisive test: The clearest route past ibogaine’s central problem is a molecule that keeps the anti-addictive effect and drops the hERG blockade. 18-Methoxycoronaridine shows a half-maximal hERG inhibitory concentration above 50 micromolar against ibogaine’s 3.5 micromolar despite similar channel binding affinity (Alper et al., 2016), and tabernanthalog, a water-soluble non-hallucinogenic analogue, reduces alcohol and heroin seeking in rodents while promoting structural plasticity (Cameron et al., 2021). If these succeed, they simultaneously validate the pharmacological account of ibogaine’s mechanism and make ibogaine itself obsolete; if they fail, that is strong evidence the subjective experience is doing part of the work.
Genotype-guided dosing as a safety pathway: Knuijver et al., 2024 established that ibogaine clearance is dominated by CYP2D6 genotype and that cardiac and cerebellar effects track the parent compound rather than the metabolite, and explicitly called for lower doses and individualised genotype-based dosing. Whether individualised dosing preserves efficacy while removing the arrhythmia risk is the key unanswered question, and no trial has yet tested it prospectively.
Evidence that could weaken the case: Two lines of work point the other way. The animal meta-analysis by Belgers et al., 2016 found no effect on conditioned place preference alongside documented cerebellar cell loss, which is difficult to reconcile with a clean reward-resetting account. And Brunt, 2026 reviews continued reports of QT prolongation and ventricular arrhythmia at therapeutic doses in people with no pre-existing cardiac condition, concluding that future use should be confined to controlled medical supervision with genotyping and rigorous cardiac monitoring. Larger and better-controlled trials could equally show that the very large open-label effect sizes shrink toward zero once expectancy and self-selection are removed.

Conclusion

Ibogaine is a plant-derived compound with an unusual profile: it acts on many targets weakly rather than one strongly, produces a day-long altered state, and appears to trigger lasting change from a single administration rather than requiring daily use. The clearest signals are the rapid ending of opioid withdrawal, a reduction in craving that persists for months, and improvement in mood, trauma symptoms and thinking in people with a history of repeated head impacts. Those signals are consistent and often large, but they rest almost entirely on small studies with no comparison group, run in people who sought and paid for treatment, so the true size of the effect is likely smaller than reported, perhaps much smaller.

The risks are better characterised than the benefits, which is rare. Ibogaine interferes with the heart’s electrical recovery and has caused fatal rhythm disturbances, including in people with no known heart problem. That hazard is measurable in advance, appears to be reducible through screening, mineral correction and multi-day monitoring, but has not been eliminated.

Much of the supporting evidence comes from clinics that sell the treatment, from advocacy organisations that promote access, and from companies developing related molecules, while the alternatives it competes with generate ongoing revenue for those who supply them. Incentives run in both directions, not one. For someone weighing this, the honest position is a compound with real and unusual promise, a real and understood way of killing people, and an evidence base too thin to settle the balance.

Top - Benefits - Risks - Protocol

Ibogaine for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Rapid Suppression of Opioid Withdrawal

Reduced Craving and Sustained Reduction in Opioid Use

Reduction in Trauma-Related, Depressive and Anxiety Symptoms After Repeated Head Trauma

Low 🟩

Improvement in Cognitive Performance After Repeated Head Trauma

Measurable Structural Brain Change After Repeated Head Trauma

Reduced Alcohol and Stimulant Use ⚠️ Conflicted

Antidepressant Effect Outside Substance Use Disorders

Speculative 🟨

Durable Reset of Entrenched Behavioural Patterns via Neuroplasticity

Neuroprotection and Support for Brain Aging

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

QT Interval Prolongation and Ventricular Arrhythmia

Fatal Outcome

Acute Ataxia, Tremor and Motor Impairment

Severe Nausea and Vomiting

Prolonged and Psychologically Demanding Altered State

Medium 🟥 🟥

Bradycardia and Hypotension

Loss of Opioid Tolerance and Elevated Overdose Risk on Relapse

Post-Treatment Insomnia and Fatigue

Low 🟥

Seizures

Persistent Psychiatric Complications

Cerebellar Neurotoxicity ⚠️ Conflicted

Hepatic Enzyme Elevation

Speculative 🟨

Cumulative Cardiac Risk with Repeated Dosing

Unknown Effects on Long-Term Neurodegenerative Risk

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion